CKRA HELPS DEVELOP THE MEDICINES OF TOMORROW!
CURRENT STUDIES
- Adolescent HPV/Meningitis Vaccine
- Adolescent Migraines
- Adolescent Smoking Cessation
- Asthma
- Female Sexual Dysfunction
- Fibromyalgia
- Fibromyalgia and Depression
- Gout (Lexington office)
- Gout (Mt. Sterling office)
- Low Testosterone
- Nocturia
- Overactive Bladder
- Smoking Cessation
- Type 2 Diabetes (study #1 - Mt. Sterling office)
- Type 2 Diabetes (study #2 - Mt. Sterling office)
-
VIEW ALL STUDIES: Lexington Mt. Sterling
SIGN UP – STUDY WAITING LIST
TESTIMONIALS
"It has been a pleasure for me to be a study participant in the important research going on at CKRA. It is exciting to be part of a study of new drugs and procedures being investigated.
The staff at Central Kentucky Research Associates is very professional; and has scheduled me in an organized and timely manner to fit my personal schedule.
Dr. James Borders and his staff are dedicated and committed individuals and a joy to work with. I personally find promise with the work they do for their clients and participants."
JCG, Lexington
Study ParticipantCKRA ON FACEBOOK
CS – Mt. Sterling
The purpose of this study is to further evaluate the efficacy of Krystexxa in adult patients with gout. Duration: Approximately 63 weeks Number of visits to CKRA: Approximately 25 Compensation: $30 per completed visit NOTE: Qualified participants must be at … Read more
The purpose of this study is to compare the effectiveness of two doses of a drug called fesoterodine to a placebo for overactive bladder. Duration: Up to 16 weeks Number of visits to CKRA: 3 to 4 Compensation: Up to … Read more
The purpose of this study is to evaluate cardiovascular outcomes after treatment with Exenatide once weekly in patients with Type 2 Diabetes. Duration: Approximately 4 years Number of visits to CKRA: Approximately 12 Compensation: Up to $30 per completed visit … Read more
The purpose of this study is to evaluate the safety and efficacy of a new medication and stigaliptin (Januvia) added to metformin in adult patients who are not adequately controlled on metformin alone or in combination with other diabetes medications. … Read more